(PRWEB) June 18, 2013
weMultiply, a New York-based angel investment and business acceleration group, has partnered with the Life Sciences Angel Network (LSAN) to support LSAN’s Third Annual MedTech Conference, and provide ongoing strategic and operational backing. Through its relationship with LSAN, weMultiply provides its engaged ventures with access to the region’s most diverse, active group of life science and Health IT angel investors and investment groups.
Launched in 2010 by Dr. Milena Adamian, LSAN funds, mentors, and provides operational support to funded companies within the life sciences and Health IT sectors. The Conference, “Build or Flip: Why and When? A Unique Look at the Medical Devices and Healthcare Services Sectors,” focused on key issues facing investors and entrepreneurs today – whether to build early-stage ventures for the ‘long haul’ or a quick sale; how to best attract and successfully engage with exit partners; and, trends and developments within the rapidly-changing markets for healthcare device and service technologies. Panelists included founders of successful Health IT and life sciences ventures, as well as industry heavyweights from organizations including Johnson & Johnson, McKinsey, Bain Capital, Bank of America, Becton Dickinson, Telcare and more.
“Partnering with LSAN offers an opportunity to be a part of the most dynamic industry conversations, as well as direct access to a wide network of active investors,” said weMultiply Managing Director Lena Feygin. “Milena’s team, as expected, has created an engaging program featuring some of the top names in the industry.”
“The markets for Health IT and life sciences technologies have seen remarkable growth in the past few years, and as these segments scale we are focused on driving the industry forward and sourcing the highest-quality opportunities,” said LSAN founder Dr. Milena Adamian. “Strategic partnerships with groups like weMultiply directly enhance our ability to target the ventures most likely to succeed in the current market climate.”
“By leveraging its network of active sales channels, weMultiply identifies and invests in ventures with a high probability of rapidly securing institutional clients,” said weMultiply Managing Director Jesse Williamson. “This approach both accelerates the implementation of innovative health technologies, and mitigates a key risk associated with early stage healthcare investments. LSAN has developed a uniquely efficient program to engage, identify and place targeted investments, and we are excited to support it.”
Backed by the 9.8 Group of Companies, weMultiply seeks out, validates, and invests in emerging health & wellness technology ventures which can benefit from its network of active institutional sales channels. The weMultiply S.A.L.E.® program provides early stage and startup companies with direct investment, access to capital through the company’s angel and venture capital networks, as well as the strategic tools, leadership, advice and health industry regulatory and compliance expertise required to ensure the proper roll-out and successful growth of each venture.
Companies accepted into the S.A.L.E.® program are provided with an aggressive development and launch program designed to prepare them for market competition and success on the global stage.
For more information on weMultiply and the S.A.L.E. program, please visit http://www.weMultiply.com.
For more information on LSAN, visit http://www.lsanfund.com.
A subsidiary of the 9.8 Group, WeMultiply empowers game-changing Health & Wellness technology innovations with the capital and strategic resources to lead in tomorrow’s market. Our program invests directly in each accelerated venture, and pairs each investment with marketing and development resources from the 9.8 Group of health care advertising agencies, its mentor network, and subsidiary businesses. Learn more at wemultiply.com.
Founded in 2010 by Dr. Milena Adamian in New York, LSAN was built with the understanding that to help our portfolio companies succeed, we needed to provide them with funding as well as operational support and an access to a broad network of healthcare investors, key opinion leaders, corporate players and other entrepreneurs.